Methods for detecting and treating autoimmune disorders
The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease.
1. A method for assessing the efficacy of a therapy in a subject with multiple sclerosis, comprising
determining the expression of FOXP3 in a first biological sample taken from a subject;
determining the expression of FOXP3 in a second biological sample taken from the subject after a period of treatment with the therapy,
wherein a difference in the expression of FOXP3 in the first biological sample as compared to the second biological sample assesses the efficacy of the therapy for treating multiple sclerosis in the subject, and wherein the first biological sample and the second biological sample comprise white blood cells,
wherein the therapy comprises administration of a therapeutically effective amount of a TCR CDR2 peptide.
2. The method of claim 1 , wherein the therapy further comprises administration of an adjuvant.
3. The method of claim 1 , wherein the TCR CDR2 peptide comprises one or more amino acid sequences as set forth in SEQ ID NOs: 1-116.
4. The method of claim 1 , wherein the therapy comprises a TCR CDR2 peptide comprising the amino acid sequence as set forth in or a TCR CDR2 peptide comprising the amino acid sequence set forth as SEQ ID NO: 73 or a TCR CDR2 peptide comprising the amino acid sequence set forth as SEQ ID NO: 90, or a combination thereof.
5. The method of claim 1 , wherein the first biological sample and the second biological sample are isolated CD4+CD25+ T cells.
6. The method of claim 4 , wherein an increase in the expression of FOXP3 in the second biological sample as compared to the expression of FOXP3 in the first biological sample indicates that the therapy is effective.
7. The method of claim 4 , wherein an decrease in the expression of FOXP3 in the second biological sample as compared to the expression of FOXP3 in the first biological sample indicates that the therapy is ineffective.
8. The method of claim 4 , wherein the therapy comprises a TCR-CDR2 peptide selected from the group consisting of aTCR CDR2 polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 62, a TCR CDR2 polypeptide comprising the amino acid sequence set forth as SEQ ID NO: 73 and a TCR CDR2 polypeptide comprising the amino acid sequence set forth as SEQ ID NO: 90.
9. The method of claim 8 , wherein the therapy further comprises administering a therapeutically effective amount of estrogen to the subject.
10. The method of claim 1 , wherein the therapy further comprises administration of a therapeutically effective amount of estrogen to the subject.
11. The method of claim 2 , wherein the adjuvant is incomplete Freud's adjuvant.
12. The method of claim 1 , wherein the multiple sclerosis comprises relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis or clinically isolated syndrome.